The European Group of Governmental Experts on Dementia held its final meeting of 2021, exchanging information and knowledge about the latest developments in dementia policy and practice. 19 countries were represented, as well as the European Commission and the WHO.
On 17 December 2021, the European Medicines Agency (EMA), in a decision closely watched by the European dementia community, decided not to authorise aducanumab for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia.
We are pleased to announce that videos of the 31st Alzheimer Europe Conference sessions (plenary, parallel and symposia) are now available on demand. If you were not previously registered for the event, but would like to gain access to these videos, you can still register for a reduced fee.
The EU-FINGERS consortium is proud to announce the official launch of its website. EU-FINGERS is, by means of a precision medicine approach, working on the topic of the prevention of Alzheimer’s disease and builds on the work of similar existing European studies.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.